1
|
Ghosh Dastidar M, Murugappan K, R Nisbet D, Tricoli A. Simultaneous electrochemical detection of glycated and human serum albumin for diabetes management. Biosens Bioelectron 2024; 246:115876. [PMID: 38039734 DOI: 10.1016/j.bios.2023.115876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 10/26/2023] [Accepted: 11/22/2023] [Indexed: 12/03/2023]
Abstract
Developing highly selective and sensitive biosensors for diabetes management blood glucose monitoring is essential to reduce the health risks associated with diabetes. Assessing the glycation (GA) of human serum albumin (HSA) serves as an indicator for medium-term glycemic control, making it suitable for assessing the efficacy of blood glucose management protocols. However, most biosensors are not capable of simultaneous detection of the relative fraction of GA to HSA in a clinically relevant range. Here, we report an effective miniaturised biosensor architecture for simultaneous electrochemical detection of HSA and GA across relevant concentration ranges. We immobilise DNA aptamers specific for the detection of HSA and GA on gold nanoislands (Au NIs) decorated screen-printed carbon electrodes (SPCEs), and effectively passivate the residual surface sites. We achieve a dynamic detection range between 20 and 60 mg/mL for HSA and 1-40 mg/mL for GA in buffer solutions. The analytical utility of our HSA and GA biosensor architectures are validated in mice serum indicating immediate potential for clinical applications. Since HSA and GA have similar structures, we extensively assess our sensor specificity, observing high selectivity of the HSA and GA sensors against each other and other commonly present interfering molecules in blood such as glucose, glycine, ampicillin, and insulin. Additionally, we determine the glycation ratio, which is a crucial metric for assessing blood glucose management efficacy, in an extensive range representing healthy and poor blood glucose management profiles. These findings provide strong evidence for the clinical potential of our biosensor architecture for point-of-care and self-assessment of diabetes management protocols.
Collapse
Affiliation(s)
- Monalisha Ghosh Dastidar
- Nanotechnology Research Laboratory, Research School of Chemistry, College of Science, Australian National University, Canberra, ACT, 2601, Australia
| | - Krishnan Murugappan
- Nanotechnology Research Laboratory, Research School of Chemistry, College of Science, Australian National University, Canberra, ACT, 2601, Australia; CSIRO, Mineral Resources, Private Bag 10, Clayton South, Victoria, 3169, Australia.
| | - David R Nisbet
- The Graeme Clark Institute, The University of Melbourne, Melbourne, Australia; Department of Biomedical Engineering, Faculty of Engineering and Information Technology, The University of Melbourne, Melbourne, Australia; Melbourne Medical School, Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Melbourne, Australia
| | - Antonio Tricoli
- Nanotechnology Research Laboratory, Research School of Chemistry, College of Science, Australian National University, Canberra, ACT, 2601, Australia; Nanotechnology Research Laboratory, Faculty of Engineering, University of Sydney, Sydney, NSW, 2006, Australia.
| |
Collapse
|
2
|
Abstract
The COVID-19 caused by a novel coronavirus, named Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has taken a great toll of life affecting lakhs of people around the globe. It was detected initially in Wuhan, China and has spread rapidly to more than 208 countries to date. A range of molecular and immunoassay-based techniques ranging from central laboratory testing to point-of-care tests is urgently needed for the diagnosis and management of COVID-19 patients. Intensive research is going on for the rapid and highly sensitive detection of COVID 19 using varied approach. Hence, this review will focus on the structure of SARS-CoV-2 and recent progress of different detection tool for the detection of COVID-19. This review will also stimulate academics and researcher to update their current technology. Additionally, we also state about the future revolving around the detection of the novel coronavirus. Lately, the way ahead for better management are also put forward.
Collapse
Affiliation(s)
- Nidhi Verma
- Department of Engineering and Physical Sciences, Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India
| | - Dhaval Patel
- Department of Biological Sciences and Biotechnology, Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India
| | - Alok Pandya
- Department of Engineering and Physical Sciences, Institute of Advanced Research, Gandhinagar, Gujarat, 382426, India.
| |
Collapse
|
3
|
Fagúndez P, Brañas G, Cairoli E, Laíz J, Tosar JP. An electrochemical biosensor for rapid detection of anti-dsDNA antibodies in absolute scale. Analyst 2018; 143:3874-3882. [DOI: 10.1039/c8an00020d] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The authors report an electrochemical biosensor enabling fast (30 min) detection of anti-DNA antibodies in serum with reduced manipulation steps.
Collapse
Affiliation(s)
- Pablo Fagúndez
- Analytical Biochemistry Unit
- Nuclear Research Center
- Faculty of Science
- Universidad de la República
- Montevideo 11400
| | - Gustavo Brañas
- Analytical Biochemistry Unit
- Nuclear Research Center
- Faculty of Science
- Universidad de la República
- Montevideo 11400
| | - Ernesto Cairoli
- Systemic Autoimmune Diseases Unit
- Clínica Médica C
- Hospital de Clínicas
- Universidad de la República
- Montevideo 11600
| | - Justo Laíz
- Analytical Biochemistry Unit
- Nuclear Research Center
- Faculty of Science
- Universidad de la República
- Montevideo 11400
| | - Juan Pablo Tosar
- Analytical Biochemistry Unit
- Nuclear Research Center
- Faculty of Science
- Universidad de la República
- Montevideo 11400
| |
Collapse
|
4
|
Liu X, Jiang H. Construction and Potential Applications of Biosensors for Proteins in Clinical Laboratory Diagnosis. SENSORS (BASEL, SWITZERLAND) 2017; 17:E2805. [PMID: 29207528 PMCID: PMC5750678 DOI: 10.3390/s17122805] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Revised: 11/20/2017] [Accepted: 11/30/2017] [Indexed: 12/11/2022]
Abstract
Biosensors for proteins have shown attractive advantages compared to traditional techniques in clinical laboratory diagnosis. In virtue of modern fabrication modes and detection techniques, various immunosensing platforms have been reported on basis of the specific recognition between antigen-antibody pairs. In addition to profit from the development of nanotechnology and molecular biology, diverse fabrication and signal amplification strategies have been designed for detection of protein antigens, which has led to great achievements in fast quantitative and simultaneous testing with extremely high sensitivity and specificity. Besides antigens, determination of antibodies also possesses great significance for clinical laboratory diagnosis. In this review, we will categorize recent immunosensors for proteins by different detection techniques. The basic conception of detection techniques, sensing mechanisms, and the relevant signal amplification strategies are introduced. Since antibodies and antigens have an equal position to each other in immunosensing, all biosensing strategies for antigens can be extended to antibodies under appropriate optimizations. Biosensors for antibodies are summarized, focusing on potential applications in clinical laboratory diagnosis, such as a series of biomarkers for infectious diseases and autoimmune diseases, and an evaluation of vaccine immunity. The excellent performances of these biosensors provide a prospective space for future antibody-detection-based disease serodiagnosis.
Collapse
Affiliation(s)
- Xuan Liu
- Department of Clinical Laboratory, The Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
| | - Hui Jiang
- School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
| |
Collapse
|
5
|
Zhang X, Zambrano A, Lin ZT, Xing Y, Rippy J, Wu T. Immunosensors for Biomarker Detection in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) 2016; 65:111-121. [PMID: 27592176 DOI: 10.1007/s00005-016-0419-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 07/04/2016] [Indexed: 01/17/2023]
Abstract
Autoimmune diseases occur when the immune system generates proinflammatory molecules and autoantibodies that mistakenly attack their own body. Traditional diagnosis of autoimmune disease is primarily based on physician assessment combined with core laboratory tests. However, these tests are not sensitive enough to detect early molecular events, and quite often, it is too late to control these autoimmune diseases and reverse tissue damage when conventional tests show positivity for disease. It is fortunate that during the past decade, research in nanotechnology has provided enormous opportunities for the development of ultrasensitive biosensors in detecting early biomarkers with high sensitivity. Biosensors consist of a biorecognition element and a transducer which are able to facilitate an accurate detection of proinflammatory molecules, autoantibodies and other disease-causing molecules. Apparently, novel biosensors could be superior to traditional metrics in assessing the drug efficacy in clinical trials, especially when specific biomarkers are indicative of the pathogenesis of disease. Furthermore, the portability of a biosensor enables the development of point-of-care devices. In this review, various types of biomolecule sensing systems, including electrochemical, optical and mechanical sensors, and their applications and future potentials in autoimmune disease treatment were discussed.
Collapse
Affiliation(s)
- Xuezhu Zhang
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA
| | - Amarayca Zambrano
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA
| | - Zuan-Tao Lin
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA
| | - Yikun Xing
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA
| | - Justin Rippy
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA
| | - Tianfu Wu
- Department Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX, 77204, USA.
| |
Collapse
|
6
|
Konstantinov KN, Tzamaloukas A, Rubin RL. Detection of autoantibodies in a point-of-care rheumatology setting. AUTO- IMMUNITY HIGHLIGHTS 2013; 4:55-61. [PMID: 26000143 PMCID: PMC4389050 DOI: 10.1007/s13317-013-0052-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Accepted: 05/02/2013] [Indexed: 11/04/2022]
Abstract
Autoimmune rheumatic diseases are common and confront society with serious medical, social, and financial burdens imposed by their debilitating nature. Many autoimmune diseases are associated with a particular set of autoantibodies, which have emerged as highly useful to define and classify disease, predict flares, or monitor efficacy of therapy. However, current practice for monitoring autoantibodies is protracted, labor-intensive, and expensive. This review provides an overview on the value of point-of-care (POC) biosensor technology in the diagnosis and management of patients with autoimmune rheumatic diseases. Real-time measurement of autoantibodies will clearly benefit the rheumatology practice in emergency and urgent care settings, where definitive diagnosis is essential for initiation of correct critical care therapy. Immediate serological information in clinic will provide considerable value for long-term patient care and an opportunity for an instant, result-deduced therapeutic action, avoiding delays and improving compliance, especially in field-based and remote areas. We describe the particular autoantibodies that are useful disease and activity markers and would, therefore, be attractive to POC applications. Already existing biosensors and platforms that show promise for autoantibody testing are summarized and comparatively evaluated. As POC assessment is gaining momentum in several areas of patient care, we propose that rheumatology is poised to benefit from this innovative and affordable technology.
Collapse
Affiliation(s)
- Konstantin N. Konstantinov
- Division of Rheumatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Mail Stop MSC10-5550, Albuquerque, NM 87131 USA
| | - Antonios Tzamaloukas
- Renal Section, Raymond G. Murphy VA Medical Center, 1501 San Pedro SE, Albuquerque, NM 87108 USA
| | - Robert L. Rubin
- Department of Molecular Genetics and Microbiology, MCS08-4660, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 USA
| |
Collapse
|
7
|
Schlichtiger A, Luppa PB, Neumeier D, Thaler M. Biosensor approaches for the detection of autoantibodies in human serum. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/s12566-012-0028-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
8
|
Electrochemical immunosensor detection of antigliadin antibodies from real human serum. Biosens Bioelectron 2011; 26:4471-6. [DOI: 10.1016/j.bios.2011.05.004] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2011] [Revised: 05/03/2011] [Accepted: 05/04/2011] [Indexed: 11/24/2022]
|
9
|
Dulay S, Lozano-Sánchez P, Iwuoha E, Katakis I, O'Sullivan CK. Electrochemical detection of celiac disease-related anti-tissue transglutaminase antibodies using thiol based surface chemistry. Biosens Bioelectron 2011; 26:3852-6. [DOI: 10.1016/j.bios.2011.02.045] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2011] [Revised: 02/23/2011] [Accepted: 02/24/2011] [Indexed: 11/28/2022]
|
10
|
Ortiz M, Fragoso A, O'Sullivan CK. Detection of Antigliadin Autoantibodies in Celiac Patient Samples Using a Cyclodextrin-Based Supramolecular Biosensor. Anal Chem 2011; 83:2931-8. [DOI: 10.1021/ac102956p] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Mayreli Ortiz
- Nanobiotechnology and Bioanalysis Group, Departament d’Enginyeria Química, Universitat Rovira i Virgili, Avinguda Països Catalans 26, 43007 Tarragona, Spain
| | - Alex Fragoso
- Nanobiotechnology and Bioanalysis Group, Departament d’Enginyeria Química, Universitat Rovira i Virgili, Avinguda Països Catalans 26, 43007 Tarragona, Spain
| | - Ciara K. O'Sullivan
- Nanobiotechnology and Bioanalysis Group, Departament d’Enginyeria Química, Universitat Rovira i Virgili, Avinguda Països Catalans 26, 43007 Tarragona, Spain
- Institució Catalana de Recerca i Estudis Avançats, Passeig Lluís Companys, 23, 08010 Barcelona, Spain
| |
Collapse
|
11
|
|
12
|
Gruhl FJ, Rapp BE, Länge K. Biosensors for diagnostic applications. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2011; 133:115-48. [PMID: 22223139 DOI: 10.1007/10_2011_130] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Biosensors combine a transducer with a biorecognition element and thus are able to transform a biochemical event on the transducer surface directly into a measurable signal. By this they have the potential to provide rapid, real-time, and accurate results in a comparatively easy way, which makes them promising analytical devices. Since the first biosensor was introduced in 1962 as an "enzyme electrode" for monitoring glucose in blood, medical applications have been the main driving force for further biosensor development. In this chapter we outline potential biosensor setups, focusing on transduction principles, biorecognition layers, and biosensor test formats, with regard to potential applications. A summary of relevant aspects concerning biosensor integration in efficient analytical setups is included. We describe the latest applications of biosensors in diagnostic applications focusing on detection of molecular biomarkers in real samples. An overview of the current state and future trends of biosensors in this field is given.
Collapse
Affiliation(s)
- Friederike J Gruhl
- Karlsruhe Institute of Technology Institute for Microstructure Technology, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
| | | | | |
Collapse
|
13
|
Cho W, Jung K, Regnier FE. Screening antibody and immunosorbent selectivity by two‐dimensional liquid chromatography‐MS/MS (2‐D LC‐MS/MS). J Sep Sci 2010; 33:1438-47. [PMID: 20405482 DOI: 10.1002/jssc.200900860] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Wonryeon Cho
- Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
| | | | | |
Collapse
|